Cargando…

Tools to identify the men with prostate cancer most appropriate for active surveillance?

Detalles Bibliográficos
Autor principal:	Getzenberg, Robert H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Invited Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901887/ https://www.ncbi.nlm.nih.gov/pubmed/24369138 http://dx.doi.org/10.4103/1008-682X.122369

Ejemplares similares

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Subaxial cervical spine injury classification system: is it most appropriate for classifying cervical injury?
por: Martínez-Pérez, Rafael, et al.
Publicado: (2015)

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity
por: Mendonca, Janet, et al.
Publicado: (2015)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

Prostate cancer screening: and yet it moves!
por: Kwiatkowski, Maciej, et al.
Publicado: (2015)

To screen or not to screen: the prostate cancer dilemma
por: Stone, Nelson N, et al.
Publicado: (2015)

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2020)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

External beam radiotherapy for localized prostate cancer
por: Yilmaz, Hasan, et al.
Publicado: (2015)

Testosterone replacement therapy and the risk of prostate cancer
por: Warburton, Daniel, et al.
Publicado: (2015)

Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019)

Androgen receptor functions in prostate cancer development and progression
por: Balk, Steven P
Publicado: (2014)

Prevention of erectile dysfunction after radiotherapy for prostate cancer
por: Faiena, Izak, et al.
Publicado: (2014)

Trading in your spindles for blebs: the amoeboid tumor cell phenotype in prostate cancer
por: Morley, Samantha, et al.
Publicado: (2014)

Are men talking their reproductive health away?
por: Agarwal, Ashok, et al.
Publicado: (2015)

Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014)

Long-term survival of participants in the prostate cancer prevention trial
por: Silberstein, Jonathan L, et al.
Publicado: (2014)

Management of localized prostate cancer: the pendulum swings (back to the middle)
por: Vuong, Winston, et al.
Publicado: (2014)

Lipogenic metabolism: a viable target for prostate cancer treatment?
por: Liang, Mengmeng, et al.
Publicado: (2014)

HOXB13 and other high penetrant genes for prostate cancer
por: Pilie, Patrick G, et al.
Publicado: (2016)

Re: Long-term survival of participants in the Prostate Cancer Prevention Trial
por: Thompson, Ian M, et al.
Publicado: (2014)

Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification
por: Chiang, Yan Ting, et al.
Publicado: (2014)

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Robotic radical prostatectomy in high-risk prostate cancer: current perspectives
por: Canda, Abdullah Erdem, et al.
Publicado: (2015)

Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods
por: Moyad, Mark A
Publicado: (2015)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014)

Relapse of prostate cancer from the viewpoint of total gland volume kinetics theory
por: Watanabe, Hiroki
Publicado: (2015)

Salvage brachytherapy for locally recurrent prostate cancer after external beam radiotherapy
por: Yamada, Yasuhiro, et al.
Publicado: (2015)

The multiple actions of testosterone in men: nature knows best
por: Funder, John W
Publicado: (2014)

Antibiotic resistance in the most unlikeliest of places
por: Bartlett, Douglas H.
Publicado: (2017)

Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?
por: Incrocci, Luca
Publicado: (2014)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Locally-advanced prostate cancer in the elderly: should we revisit our treatment paradigms?
por: Lughezzani, Giovanni, et al.
Publicado: (2015)

Appraising the European randomized study of screening for prostate cancer: what do the results mean?
por: Ilic, Dragan
Publicado: (2015)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment
por: Lv, Jialu, et al.
Publicado: (2020)

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s5jtp5mjv8m8334b7jpmvdfo9f